SCHEMBL29935801

SCHEMBL29935801

Cn1cnc2cc(Oc3ccc(N)c(F)c3)ccc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.46
GAA P10253 4/20 0.45
HPGD P15428 3/20 0.45
DDB1 Q16531 1/20 0.41
CRBN Q96SW2 1/20 0.41
ALDH1A1 P00352 4/20 0.41
MAPT P10636 3/20 0.41
KDM4E B2RXH2 3/20 0.41
FGFR1 P11362 3/20 0.40
GRM5 P41594 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.37
SIGMAR1 Q99720 2/20 0.37
DRD4 P21917 1/20 0.37
DYRK1A Q13627 1/20 0.37
NR4A1 P22736 1/20 0.36
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
HSD17B10 Q99714 2/20 0.36
LMNA P02545 1/20 0.36
ALOX15 P16050 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23750168 1.00 KMT2A (0.46) KMT2AGAAHPGDDDB1CRBN
SCHEMBL24173326 0.83 KMT2A (0.44) KMT2AGAAHPGDDDB1CRBN
SCHEMBL24569506 0.82 FGFR1 (0.54) KMT2AGAAHPGDDDB1CRBN
SCHEMBL24807834 0.82 KMT2A (0.41) KMT2AGAAHPGDDDB1CRBN
SCHEMBL30050459 0.82 KMT2A (0.41) KMT2AGAAHPGDDDB1CRBN
SCHEMBL23750167 0.82 KMT2A (0.45) KMT2AGAAHPGDDDB1CRBN
SCHEMBL29887844 0.81 KMT2A (0.44) KMT2AGAAHPGDDDB1CRBN
SCHEMBL24569478 0.81 KMT2A (0.44) KMT2AGAAHPGDDDB1CRBN
SCHEMBL23750358 0.80 KMT2A (0.43) KMT2AGAAHPGDDDB1CRBN
SCHEMBL29888756 0.80 KMT2A (0.43) KMT2AGAAHPGDDDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118459485-A Amino-substituted heterocycles for the treatment of cancers with EGFR mutations 纽威伦特公司 2024-08-09 CN disclosed
EP-4323356-A1 AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS Nuvalent, Inc. (US) 2024-02-21 EP disclosed
CN-117500803-A Amino-substituted heterocycles for the treatment of cancers with EGFR mutations 纽威伦特公司 2024-02-02 CN disclosed
WO-2022221227-A9 AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS NUVALENT, INC. (US) 2023-11-30 WO disclosed
WO-2022221227-A1 AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS NUVALENT, INC. (US) 2022-10-20 WO disclosed